Sector News

Google, Mayo Clinic build new type of AI algorithm to map interactions between areas of the brain

September 12, 2021
Life sciences

Neurostimulation is a powerful tool that is already being used to treat chronic pain, anxious depression, overactive bladder and more by sending electrical pulses to areas of the brain linked to each condition.

Despite the technology’s proven success, however, it only works if the correct areas of the brain are stimulated—a task often easier said than done.

To provide a map showing the way forward, the Mayo Clinic and Google Research’s Brain Team are developing a new type of artificial intelligence algorithm to chart out the neural connections spanning each region of the brain.

Using a technique dubbed “basis profile curve identification,” the algorithm goes deeper than traditional methods, where researchers monitor all regions of the brain for widespread reactions to electrical pulses sent to just one area at a time. That method is limited by the difficulty of measuring potentially thousands of network interactions at once, many of which take complex, unique forms that can’t be measured by this “one-size-fits-all” framework.

Instead, the Mayo and Google researchers implanted an electrode array on the surface of the brain of a patient with a brain tumor. Before the tumor’s removal, the electrodes were repeatedly activated in short bursts. With each activation, the researchers collected anywhere from hundreds to thousands of data points indicating an individual impulse’s effects on certain regions of the brain.

From there, the AI algorithm was tasked with analyzing those thousands of interactions, characterizing them by their shapes and compiling them into a map of the web of connections across the entire brain.

This process was detailed in a study published this month in the journal PLOS Computational Biology, which also gives other scientists access to the new AI technique to apply it to their own neurological research projects.

“Our findings show that this new type of algorithm may help us understand which brain regions directly interact with one another, which in turn may help guide placement of electrodes for stimulating devices to treat network brain diseases,” said Kai Miller, M.D., Ph.D., the study’s lead author and a Mayo Clinic neurosurgeon.

“As new technology emerges, this type of algorithm may help us to better treat patients with epilepsy, movement disorders like Parkinson’s disease and psychiatric illnesses like obsessive compulsive disorder and depression,” Miller added.

The new algorithm is the latest product of Mayo and Google Research’s long-standing partnership. The duo originally teamed up in 2019, at which time the partners laid out a decade’s worth of research collaborations build around Google’s cloud computing and AI technologies.

Since then, after immediately beginning the work of transferring Mayo’s expansive repositories of patient health data to the Google Cloud servers, they’ve combined those data and Google’s AI to build algorithms to improve cancer radiotherapy and COVID-19 tracking.

Plus, earlier this year, in a show of devotion to its Minnesota-based partner, Google opened up its own satellite office just down the street from Mayo’s Rochester campus.

by Andrea Park

Source: fiercebiotech.com

comments closed

Related News

September 12, 2021

Sanofi to buy Kadmon for $1.9B, extending deal streak

Life sciences

The deal, announced Wednesday, has Sanofi paying $9.50 per share in cash for Kadmon, a roughly 77% premium to the biotech’s Tuesday closing price and 113% more than its average trading price over the last two months.

September 12, 2021

GSK, Pfizer and Johnson & Johnson race toward $10B-plus RSV vaccine market: analyst

Life sciences

RSV, or respiratory syncytial virus, has long been a top target for vaccine developers. While companies have suffered high-profile trial failures over the years, vaccines are now advancing through late-stage testing and could launch in 2023, SVB Leerink analyst Geoffrey Porges wrote to clients this week.

September 12, 2021

Theranos founder Elizabeth Holmes’ defense paints her as a ‘naive’ but ambitious CEO in fraud trial opening statement

Life sciences

As Elizabeth Holmes’ federal fraud trial began, in response to prosecutors’ claims that she knowingly defrauded investors, partners and patients in pursuit of fame and wealth, the former Theranos founder and CEO’s defense team described her as merely an inexperienced leader who made serious mistakes.

Send this to a friend